Search Our Site

News tagged with:

"cancer-treatment"

Localized prostate cancer treatment options lead to different sexual functioning, quality-of-life outcomes

Men with localized prostate cancer experienced different adverse events and quality-of-life changes according to whether they underwent surgery, radiation or active surveillance, according to two studies published in JAMA. In one study, Daniel A. Barocas, MD, MPH, urologic surgeon and oncologist in the department of urologic surgery at Vanderbilt University Medical Center, and colleagues found... Read More »

Read More →

Men with localized prostate cancer experienced different adverse events and quality-of-life changes according to whether they underwent surgery, radiation or active surveillance, according to two studies published in JAMA. In one study, Daniel A. Barocas, MD, MPH, urologic surgeon and oncologist in the department of urologic surgery at Vanderbilt University Medical Center, and colleagues found… Read More »

[...]

Read More

Bayer Seeks FDA Approval For Regorafenib As Liver Cancer Treatment

German pharmaceutical company Bayer is seeking the approval of federal health regulators to have its drug Stivarga (Regorafenib) as second-line treatment for liver cancer patients. On Monday, Bayer submitted a New Drug Application (sNDA) to the United States Food and Drug Administration (FDA) following successful clinical trials for regorafenib in treating unresectable hepatocellular carcinoma (uHCC). Bayer, which... Read More »

Read More →

German pharmaceutical company Bayer is seeking the approval of federal health regulators to have its drug Stivarga (Regorafenib) as second-line treatment for liver cancer patients. On Monday, Bayer submitted a New Drug Application (sNDA) to the United States Food and Drug Administration (FDA) following successful clinical trials for regorafenib in treating unresectable hepatocellular carcinoma (uHCC). Bayer, which… Read More »

[...]

Read More

‘New day’ in lung cancer as Merck drug shines, works with chemo

Merck & Co scored a double hit on Sunday with new clinical data showing its Keytruda immunotherapy offered big benefits in previously untreated lung cancer patients, either when given on its own or with chemotherapy. As a monotherapy, Keytruda halved the risk of disease progression and cut overall deaths by 40 percent compared to chemotherapy... Read More »

Read More →

Merck & Co scored a double hit on Sunday with new clinical data showing its Keytruda immunotherapy offered big benefits in previously untreated lung cancer patients, either when given on its own or with chemotherapy. As a monotherapy, Keytruda halved the risk of disease progression and cut overall deaths by 40 percent compared to chemotherapy… Read More »

[...]

Read More
Categories
Archives